Bimekizumab. Humanized monoclonal antibody demonstrating dual inhibition of IL-17A and IL-17F, Treatment of psoriasis and psoriatic arthritis
Author:
- 1 January 2018
- journal article
- research article
- Published by Portico in Drugs of the Future
- Vol. 43 (7) , 0483-487